Newsletter | February 17, 2021

02.17.21 -- CEO Q&A: Mary Szela

Featured Articles
CEO Q&A: Mary Szela

Mary Szela spent 25 years in Big Pharma and the last seven at three small biotechs. The CEO Of TriSalus Life Sciences discusses how she adapted during these career changes and some of the difficulties she encountered along the way.

Companies To Watch: Akero Therapeutics

Companies To Watch: Akero Therapeutics — Test-proofing a new metabolism drug to beat the liver disease, NASH.

RNA’s Rousing New Adventure

Dicerna shows how the multitude of “co-opportunities” of COVID in the RNA space has further encouraged companies to exploit the unique attributes of those approaches well beyond dealing with the immediate viral threat.

Web-Exclusive Content
3 Strategies To Address The Biggest Concerns Facing Generic Drug Makers

Amid this opportunity for generic drug makers to capitalize on patent expiration, they’re facing struggles around pricing power. COVID-19 also exposed the fragility of supply chains that were built with economic efficiency rather than resiliency in mind.

025: Are Decentralized Trials Finally Here To Stay?

Will decentralized clinical trials continue to be a hot topic even after the pandemic or will pharma companies revert to their old ways. Our guest, editor, Ed Miseta, weighs in on this timely topic.

February 2021 Digital Edition

Inside you will find more on:

  • Outsourcing Market Data
  • Artificial Intelligence In Biopharma
  • Capitol Perspectives
  • Leadership Lessons

View the digital edition.

Contribute To Life Science Leader
Article Submission Guidelines

Think you have a good idea for an article that Life Science Leader readers would find valuable? Read these guidelines first before submitting your idea or your article to our editorial director.